{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:23:48Z","timestamp":1789759428375,"version":"4.0.1"},"reference-count":100,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2011.0399","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:20:20Z","timestamp":1525252820000},"source":"Crossref","is-referenced-by-count":22,"title":["The Diagnosis and Treatment of Autoimmune Blistering Skin Diseases"],"prefix":"10.3238","author":[{"given":"Enno","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2011,6,10]]},"reference":[{"key":"10.3238\/arztebl.2011.0399_ref1","doi-asserted-by":"crossref","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J: Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.","DOI":"10.1136\/bmj.a180"},{"key":"10.3238\/arztebl.2011.0399_ref2","doi-asserted-by":"crossref","unstructured":"Schmidt E, D\u00e4hnrich C, Rosemann A, et al.: Novel ELISA systems for antibodies to desmoglein 1 and 3: Correlation of disease activity with serum autoantibody levels in individual pemphigus patients. 2010; 19: 458\u201363.","DOI":"10.1111\/j.1600-0625.2010.01069.x"},{"key":"10.3238\/arztebl.2011.0399_ref3","doi-asserted-by":"crossref","unstructured":"Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB: Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850\u20131.","DOI":"10.1016\/S0140-6736(00)04971-0"},{"key":"10.3238\/arztebl.2011.0399_ref4","doi-asserted-by":"crossref","unstructured":"Zillikens D, Kawahara Y, Ishiko A, et al.: A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106: 1333\u20138.","DOI":"10.1111\/1523-1747.ep12349283"},{"key":"10.3238\/arztebl.2011.0399_ref5","doi-asserted-by":"crossref","unstructured":"Dainichi T, Kurono S, Ohyama B, et al.: Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009; 106: 2800\u20135.","DOI":"10.1073\/pnas.0809230106"},{"key":"10.3238\/arztebl.2011.0399_ref6","doi-asserted-by":"crossref","unstructured":"Woodley DT, Briggaman RA, O\u2019Keefe EJ, Inman AO, Queen LL, Gammon WR: Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007\u201313.","DOI":"10.1056\/NEJM198404193101602"},{"key":"10.3238\/arztebl.2011.0399_ref7","doi-asserted-by":"crossref","unstructured":"Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N: Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747\u201357.","DOI":"10.1084\/jem.20011299"},{"key":"10.3238\/arztebl.2011.0399_ref8","doi-asserted-by":"crossref","unstructured":"Schmidt E, Obe K, Brocker EB, Zillikens D: Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136: 174\u20138.","DOI":"10.1001\/archderm.136.2.174"},{"key":"10.3238\/arztebl.2011.0399_ref9","doi-asserted-by":"crossref","unstructured":"Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D: Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2005; CD002292.","DOI":"10.1002\/14651858.CD002292.pub2"},{"key":"10.3238\/arztebl.2011.0399_ref10","doi-asserted-by":"crossref","unstructured":"Martin LK, Werth V, Villanueva E, Segall J, Murrell DF: Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; CD006263.","DOI":"10.1002\/14651858.CD006263.pub2"},{"key":"10.3238\/arztebl.2011.0399_ref11","doi-asserted-by":"crossref","unstructured":"Harman KE, Albert S, Black MM: Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926\u201337.","DOI":"10.1111\/j.1365-2133.2003.05665.x"},{"key":"10.3238\/arztebl.2011.0399_ref12","doi-asserted-by":"crossref","unstructured":"Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP: Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214\u201321.","DOI":"10.1046\/j.1365-2133.2002.04835.x"},{"key":"10.3238\/arztebl.2011.0399_ref13","doi-asserted-by":"crossref","unstructured":"Chan LS, Ahmed AR, Anhalt GJ, et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370\u20139.","DOI":"10.1001\/archderm.138.3.370"},{"key":"10.3238\/arztebl.2011.0399_ref14","doi-asserted-by":"crossref","unstructured":"Joly P, Roujeau JC, Benichou J, et al.: A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321\u20137.","DOI":"10.1056\/NEJMoa011592"},{"key":"10.3238\/arztebl.2011.0399_ref15","doi-asserted-by":"crossref","unstructured":"Beissert S, Werfel T, Frieling U, et al.: A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447\u201354.","DOI":"10.1001\/archderm.142.11.1447"},{"key":"10.3238\/arztebl.2011.0399_ref16","doi-asserted-by":"crossref","unstructured":"Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.: Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622\u20138.","DOI":"10.1016\/j.jaad.2007.05.024"},{"key":"10.3238\/arztebl.2011.0399_ref17","doi-asserted-by":"crossref","unstructured":"Amagai M, Ikeda S, Shimizu H, et al.: A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595\u2013603.","DOI":"10.1016\/j.jaad.2008.09.052"},{"key":"10.3238\/arztebl.2011.0399_ref18","doi-asserted-by":"crossref","unstructured":"Enk A, Fierlbeck G, French L, et al.: Use of high-dose immuno-globulins in dermatology. J Dtsch Dermatol Ges 2009; 7: 806\u201312.","DOI":"10.1111\/j.1610-0387.2009.07118.x"},{"key":"10.3238\/arztebl.2011.0399_ref19","doi-asserted-by":"crossref","unstructured":"Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA: Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189\u201396.","DOI":"10.1056\/NEJM198205203062001"},{"key":"10.3238\/arztebl.2011.0399_ref20","doi-asserted-by":"crossref","unstructured":"Sitaru C, Mihai S, Otto C, et al.: Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 2005; 115: 870\u20138.","DOI":"10.1172\/JCI200521386"},{"key":"10.3238\/arztebl.2011.0399_ref21","doi-asserted-by":"crossref","unstructured":"Schmidt E, Klinker E, Opitz A, et al.: Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148: 1222\u20139.","DOI":"10.1046\/j.1365-2133.2003.05302.x"},{"key":"10.3238\/arztebl.2011.0399_ref22","doi-asserted-by":"crossref","unstructured":"Zillikens D, Derfler K, Eming R, et al.: Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881\u20137.","DOI":"10.1111\/j.1610-0387.2007.06342.x"},{"key":"10.3238\/arztebl.2011.0399_ref23","doi-asserted-by":"crossref","unstructured":"Nagel A, Hertl M, Eming R: B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 2009; 129: 289\u2013301.","DOI":"10.1038\/jid.2008.192"},{"key":"10.3238\/arztebl.2011.0399_ref24","doi-asserted-by":"crossref","unstructured":"Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M: Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352\u20136.","DOI":"10.1111\/j.1365-2133.2006.07646.x"},{"key":"10.3238\/arztebl.2011.0399_ref25","doi-asserted-by":"crossref","unstructured":"Hertl M, Zillikens D, Borradori L, et al.: Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366\u201373.","DOI":"10.1111\/j.1610-0387.2007.06602.x"},{"key":"10.3238\/arztebl.2011.0399_ref26","doi-asserted-by":"crossref","unstructured":"Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T: The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167\u201370.","DOI":"10.1016\/S0190-9622(99)70183-0"},{"key":"10.3238\/arztebl.2011.0399_ref27","doi-asserted-by":"crossref","unstructured":"Anhalt GJ, Kim SC, Stanley JR, et al.: Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729\u201335.","DOI":"10.1056\/NEJM199012203232503"},{"key":"10.3238\/arztebl.2011.0399_ref28","doi-asserted-by":"crossref","unstructured":"Anhalt GJ: Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29\u201333.","DOI":"10.1111\/j.1087-0024.2004.00832.x"},{"key":"10.3238\/arztebl.2011.0399_ref29","doi-asserted-by":"crossref","unstructured":"Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E: Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010; 8: 598\u2013605.","DOI":"10.1111\/j.1610-0387.2010.07380.x"},{"key":"10.3238\/arztebl.2011.0399_ref30","doi-asserted-by":"crossref","unstructured":"Kippes W, Schmidt E, Roth A, Rzany B, Brocker EB, Zillikens D: Immunopathologic changes in 115 patients with bullous pemphigoid. Hautarzt 1999; 50: 866\u201372.","DOI":"10.1007\/s001050051001"},{"key":"10.3238\/arztebl.2011.0399_ref31","doi-asserted-by":"crossref","unstructured":"Hahn-Ristic K, Rzany B, Amagai M, Brocker EB, Zillikens D: Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol 2002; 16: 68\u201371.","DOI":"10.1046\/j.1468-3083.2002.00384.x"},{"key":"10.3238\/arztebl.2011.0399_ref32","doi-asserted-by":"crossref","unstructured":"Bernard P, Vaillant L, Labeille B, et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48\u201352.","DOI":"10.1001\/archderm.131.1.48"},{"key":"10.3238\/arztebl.2011.0399_ref33","doi-asserted-by":"crossref","unstructured":"Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Brocker EB: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957\u20138.","DOI":"10.1001\/archderm.131.8.957"},{"key":"10.3238\/arztebl.2011.0399_ref34","doi-asserted-by":"crossref","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E: Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434\u201340.","DOI":"10.1111\/j.1610-0387.2008.06976.x"},{"key":"10.3238\/arztebl.2011.0399_ref35","doi-asserted-by":"crossref","unstructured":"Marazza G, Pham HC, Scharer L, et al.: Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861\u20138.","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"10.3238\/arztebl.2011.0399_ref36","doi-asserted-by":"crossref","unstructured":"Jung M, Kippes W, Messer G, Zillikens D, Rzany B: Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol 1999; 41: 266\u20138.","DOI":"10.1016\/S0190-9622(99)70061-7"},{"key":"10.3238\/arztebl.2011.0399_ref37","doi-asserted-by":"crossref","unstructured":"Beutner EH, Jordon RE: Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med 1964; 117: 505\u201310.","DOI":"10.3181\/00379727-117-29622"},{"key":"10.3238\/arztebl.2011.0399_ref38","doi-asserted-by":"crossref","unstructured":"Kelly SE, Wojnarowska F: The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118: 31\u201340.","DOI":"10.1111\/j.1365-2133.1988.tb01747.x"},{"key":"10.3238\/arztebl.2011.0399_ref39","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D: Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 2009; 7: 296\u2013300.","DOI":"10.1111\/j.1610-0387.2008.06974.x"},{"key":"10.3238\/arztebl.2011.0399_ref40","doi-asserted-by":"crossref","unstructured":"Amagai M, Komai A, Hashimoto T, et al.: Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 351\u20137.","DOI":"10.1046\/j.1365-2133.1999.02752.x"},{"key":"10.3238\/arztebl.2011.0399_ref41","doi-asserted-by":"crossref","unstructured":"Ishii K, Amagai M, Hall RP, et al.: Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010\u20137.","DOI":"10.4049\/jimmunol.159.4.2010"},{"key":"10.3238\/arztebl.2011.0399_ref42","doi-asserted-by":"crossref","unstructured":"Nagata Y, Karashima T, Watt FM, Salmhofer W, Kanzaki T, Hashimoto T: Paraneoplastic pemphigus sera react strongly with multiple epitopes on the various regions of envoplakin and periplakin, except for the c-terminal homologous domain of periplakin. J Invest Dermatol 2001; 116: 556\u201363.","DOI":"10.1046\/j.1523-1747.2001.01263.x"},{"key":"10.3238\/arztebl.2011.0399_ref43","doi-asserted-by":"crossref","unstructured":"Zhang B, Zheng R, Wang J, Bu D, Zhu X: Epitopes in the linker subdomain region of envoplakin recognized by autoantibodies in paraneoplastic pemphigus patients. J Invest Dermatol 2006; 126: 832\u201340.","DOI":"10.1038\/sj.jid.5700198"},{"key":"10.3238\/arztebl.2011.0399_ref44","doi-asserted-by":"crossref","unstructured":"Probst C, Schlumberger W, Stocker W, et al.: Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410: 13\u20138.","DOI":"10.1016\/j.cca.2009.08.022"},{"key":"10.3238\/arztebl.2011.0399_ref45","doi-asserted-by":"crossref","unstructured":"Zillikens D, Mascaro JM, Rose PA, et al.: A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679\u201383.","DOI":"10.1111\/1523-1747.ep12338088"},{"key":"10.3238\/arztebl.2011.0399_ref46","doi-asserted-by":"crossref","unstructured":"Sitaru C, Dahnrich C, Probst C, et al.: Enzyme-linked immuno-sorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770\u20137.","DOI":"10.1111\/j.1600-0625.2007.00592.x"},{"key":"10.3238\/arztebl.2011.0399_ref47","doi-asserted-by":"crossref","unstructured":"Kromminga A, Scheckenbach C, Georgi M, et al.: Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 2000; 15: 293\u2013300.","DOI":"10.1006\/jaut.2000.0437"},{"key":"10.3238\/arztebl.2011.0399_ref48","doi-asserted-by":"crossref","unstructured":"Mulyowa GK, Jaeger G, Kabakyenga J, Brocker EB, Zillikens D, Schmidt E: Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol 2006; 45: 1047\u201352.","DOI":"10.1111\/j.1365-4632.2006.02750.x"},{"key":"10.3238\/arztebl.2011.0399_ref49","doi-asserted-by":"crossref","unstructured":"Iwata Y, Komura K, Kodera M, et al.: Correlation of IgE autoanti-body to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 41\u20138.","DOI":"10.1001\/archdermatol.2007.9"},{"key":"10.3238\/arztebl.2011.0399_ref50","doi-asserted-by":"crossref","unstructured":"Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D: IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577\u201383.","DOI":"10.1067\/mjd.2000.103986"},{"key":"10.3238\/arztebl.2011.0399_ref51","doi-asserted-by":"crossref","unstructured":"Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D: Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 2004; 111: 146\u201352.","DOI":"10.1016\/j.clim.2003.12.007"},{"key":"10.3238\/arztebl.2011.0399_ref52","doi-asserted-by":"crossref","unstructured":"Schmidt E, Kromminga A, Mimietz S, et al.: A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. J Autoimmun 2002; 18: 299\u2013309.","DOI":"10.1006\/jaut.2002.0589"},{"key":"10.3238\/arztebl.2011.0399_ref53","doi-asserted-by":"crossref","unstructured":"Yoshida M, Hamada T, Amagai M, et al.: Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006; 41: 21\u201330.","DOI":"10.1016\/j.jdermsci.2005.11.002"},{"key":"10.3238\/arztebl.2011.0399_ref54","doi-asserted-by":"crossref","unstructured":"Chan LS: Epitope spreading in paraneoplastic pemphigus: autoimmune induction in antibody-mediated blistering skin diseases. Arch Dermatol 2000; 136: 663\u20134.","DOI":"10.1001\/archderm.136.5.663"},{"key":"10.3238\/arztebl.2011.0399_ref55","doi-asserted-by":"crossref","unstructured":"Sitaru C, Powell J, Messer G, Brocker EB, Wojnarowska F, Zillikens D: Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol 2004; 103: 757\u201363.","DOI":"10.1097\/01.AOG.0000115506.76104.ad"},{"key":"10.3238\/arztebl.2011.0399_ref56","doi-asserted-by":"crossref","unstructured":"Di Zenzo G, Calabresi V, Grosso F, Caproni M, Ruffelli M, Zambruno G: The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 2007; 127: 864\u201373.","DOI":"10.1038\/sj.jid.5700594"},{"key":"10.3238\/arztebl.2011.0399_ref57","doi-asserted-by":"crossref","unstructured":"Tamada Y, Yokochi K, Nitta Y, Ikeya T, Hara K, Owaribe K: Lichen planus pemphigoides: identification of 180 kd hemidesmosome antigen. J Am Acad Dermatol 1995; 32: 883\u20137.","DOI":"10.1016\/0190-9622(95)91554-0"},{"key":"10.3238\/arztebl.2011.0399_ref58","doi-asserted-by":"crossref","unstructured":"Zillikens D, Caux F, Mascaro JM, et al.: Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113: 117\u201321.","DOI":"10.1046\/j.1523-1747.1999.00618.x"},{"key":"10.3238\/arztebl.2011.0399_ref59","doi-asserted-by":"crossref","unstructured":"Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ: LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734\u20138.","DOI":"10.1111\/1523-1747.ep12345782"},{"key":"10.3238\/arztebl.2011.0399_ref60","doi-asserted-by":"crossref","unstructured":"Zillikens D, Herzele K, Georgi M, et al.: Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801. J Invest Dermatol 1999; 113: 947\u201353.","DOI":"10.1046\/j.1523-1747.1999.00808.x"},{"key":"10.3238\/arztebl.2011.0399_ref61","doi-asserted-by":"crossref","unstructured":"Schmidt E, Skrobek C, Kromminga A, et al.: Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778\u201383.","DOI":"10.1046\/j.1365-2133.2001.04471.x"},{"key":"10.3238\/arztebl.2011.0399_ref62","doi-asserted-by":"crossref","unstructured":"Oyama N, Setterfield JF, Powell AM, et al.: Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154: 90\u20138.","DOI":"10.1111\/j.1365-2133.2005.06998.x"},{"key":"10.3238\/arztebl.2011.0399_ref63","doi-asserted-by":"crossref","unstructured":"Bedane C, McMillan JR, Balding SD, et al.: Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108: 901\u20137.","DOI":"10.1111\/1523-1747.ep12292701"},{"key":"10.3238\/arztebl.2011.0399_ref64","doi-asserted-by":"crossref","unstructured":"Lazarova Z, Hsu R, Yee C, Yancey KB: Antiepiligrin cicatricial pemphigoid represents an autoimmune response to subunits present in laminin 5 (alpha3beta3gamma2). Br J Dermatol 1998; 139: 791\u20137.","DOI":"10.1046\/j.1365-2133.1998.02502.x"},{"key":"10.3238\/arztebl.2011.0399_ref65","doi-asserted-by":"crossref","unstructured":"Leverkus M, Schmidt E, Lazarova Z, Brocker EB, Yancey KB, Zillikens D: Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? Arch Dermatol 1999; 135: 1091\u20138.","DOI":"10.1001\/archderm.135.9.1091"},{"key":"10.3238\/arztebl.2011.0399_ref66","doi-asserted-by":"crossref","unstructured":"Lapiere JC, Woodley DT, Parente MG, et al.: Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest 1993; 92: 1831\u20139.","DOI":"10.1172\/JCI116774"},{"key":"10.3238\/arztebl.2011.0399_ref67","doi-asserted-by":"crossref","unstructured":"Rose C, Armbruster FP, Ruppert J, Igl BW, Zillikens D, Shimanovich I: Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009; 61: 39\u201343.","DOI":"10.1016\/j.jaad.2008.12.037"},{"key":"10.3238\/arztebl.2011.0399_ref68","doi-asserted-by":"crossref","unstructured":"Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM: The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol 2001; 144: 775\u201380.","DOI":"10.1046\/j.1365-2133.2001.04132.x"},{"key":"10.3238\/arztebl.2011.0399_ref69","doi-asserted-by":"crossref","unstructured":"Hofmann SC, Kautz O, Hertl M, Sticherling M, Zillikens D, Bruckner-Tuderman L: Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid. J Dtsch Dermatol Ges 2009; 7: 227\u201333.","DOI":"10.1111\/j.1610-0387.2008.06872.x"},{"key":"10.3238\/arztebl.2011.0399_ref70","doi-asserted-by":"crossref","unstructured":"Goebeler M, Sitaru C, Zillikens D: Blistering autoimmune dermatoses (II): therapy. J Dtsch Dermatol Ges 2004; 2: 774\u201391.","DOI":"10.1046\/j.1439-0353.2004.04517.x"},{"key":"10.3238\/arztebl.2011.0399_ref71","doi-asserted-by":"crossref","unstructured":"Mutasim DF: Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859\u201377; quiz 878\u201380.","DOI":"10.1016\/j.jaad.2004.02.013"},{"key":"10.3238\/arztebl.2011.0399_ref72","doi-asserted-by":"crossref","unstructured":"Bystryn JC, Rudolph JL: Pemphigus. Lancet 2005; 366: 61\u201373.","DOI":"10.1016\/S0140-6736(05)66829-8"},{"key":"10.3238\/arztebl.2011.0399_ref73","doi-asserted-by":"crossref","unstructured":"Kasperkiewicz M, Schmidt E: Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009; 6: 270\u201380.","DOI":"10.2174\/157016309789869065"},{"key":"10.3238\/arztebl.2011.0399_ref74","doi-asserted-by":"crossref","unstructured":"Rosenberg FR, Sanders S, Nelson CT: Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962\u201370.","DOI":"10.1001\/archderm.112.7.962"},{"key":"10.3238\/arztebl.2011.0399_ref75","unstructured":"Benoit S, Br\u00f6cker EB, Schmidt E: Current treatment of pemphigus. G Ital Dermatol Venereol 2007; 142: 363\u201380."},{"key":"10.3238\/arztebl.2011.0399_ref76","doi-asserted-by":"crossref","unstructured":"Kirtschig G, Murrell D, Wojnarowska F, Khumalo N: Interventions for mucous membrane pemphigoid\/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380\u20134.","DOI":"10.1001\/archderm.138.3.380"},{"key":"10.3238\/arztebl.2011.0399_ref77","doi-asserted-by":"crossref","unstructured":"Joly P, Roujeau JC, Benichou J, et al.: A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009; 129: 1681\u20137.","DOI":"10.1038\/jid.2008.412"},{"key":"10.3238\/arztebl.2011.0399_ref78","doi-asserted-by":"crossref","unstructured":"El-Darouti M, Marzouk S, Abdel Hay R, et al.: The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: a comparative study. Br J Dermatol 2009; 161: 313\u20139.","DOI":"10.1111\/j.1365-2133.2009.09208.x"},{"key":"10.3238\/arztebl.2011.0399_ref79","doi-asserted-by":"crossref","unstructured":"Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ: Treating pemphigus vulgaris with prednisone and mycophenolate Mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041\u20138.","DOI":"10.1038\/jid.2010.91"},{"key":"10.3238\/arztebl.2011.0399_ref80","doi-asserted-by":"crossref","unstructured":"Cooper SM, Powell J, Wojnarowska F: Linear IgA disease: successful treatment with erythromycin. Clin Exp Dermatol 2002; 27: 677\u20139.","DOI":"10.1046\/j.1365-2230.2002.01133.x"},{"key":"10.3238\/arztebl.2011.0399_ref81","doi-asserted-by":"crossref","unstructured":"Schmidt E, Meyer-Ter-Vehn T, Zillikens D, Geerling G: Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis. Ophthalmologe 2008; 105: 285\u201397.","DOI":"10.1007\/s00347-008-1699-x"},{"key":"10.3238\/arztebl.2011.0399_ref82","doi-asserted-by":"crossref","unstructured":"Meyer-ter-Vehn T, Schmidt E, Zillikens D, Geerling G: Mucous membrane pemphigoid with ocular involvement. Part II: therapy. Ophthalmologe 2008; 105: 405\u201319.","DOI":"10.1007\/s00347-008-1700-8"},{"key":"10.3238\/arztebl.2011.0399_ref83","doi-asserted-by":"crossref","unstructured":"Saw VP, Dart JK, Rauz S, et al.: Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 2008; 115: 253\u2013261.","DOI":"10.1016\/j.ophtha.2007.04.027"},{"key":"10.3238\/arztebl.2011.0399_ref84","unstructured":"Foster CS: Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527\u2013663."},{"key":"10.3238\/arztebl.2011.0399_ref85","doi-asserted-by":"crossref","unstructured":"Ishii N, Hashimoto K, Zillikens D, Ludwig RJ: High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186\u201395.","DOI":"10.1007\/s12016-009-8153-y"},{"key":"10.3238\/arztebl.2011.0399_ref86","doi-asserted-by":"crossref","unstructured":"Engineer L, Bhol KC, Ahmed AR: Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049\u201357.","DOI":"10.1067\/mjd.2000.108366"},{"key":"10.3238\/arztebl.2011.0399_ref87","doi-asserted-by":"crossref","unstructured":"Ahmed AR: Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679\u201390.","DOI":"10.1067\/mjd.2001.116339"},{"key":"10.3238\/arztebl.2011.0399_ref88","doi-asserted-by":"crossref","unstructured":"Herzog S, Schmidt E, Goebeler M, Brocker EB, Zillikens D: Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84: 48\u201352.","DOI":"10.1080\/00015550310005861"},{"key":"10.3238\/arztebl.2011.0399_ref89","doi-asserted-by":"crossref","unstructured":"Czernik A, Bystryn JC: Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies. Arch Dermatol 2008; 144: 658\u201361.","DOI":"10.1001\/archderm.144.5.658"},{"key":"10.3238\/arztebl.2011.0399_ref90","doi-asserted-by":"crossref","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y: Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257\u20139.","DOI":"10.1016\/j.autrev.2006.08.011"},{"key":"10.3238\/arztebl.2011.0399_ref91","doi-asserted-by":"crossref","unstructured":"Amagai M, Hashimoto T, Shimizu N, Nishikawa T: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59\u201367.","DOI":"10.1172\/JCI117349"},{"key":"10.3238\/arztebl.2011.0399_ref92","doi-asserted-by":"crossref","unstructured":"Liu Z, Diaz LA, Troy JL, et al.: A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 2480\u20138.","DOI":"10.1172\/JCI116856"},{"key":"10.3238\/arztebl.2011.0399_ref93","doi-asserted-by":"crossref","unstructured":"Sitaru C, Chiriac MT, Mihai S, et al.: Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 2006; 177: 3461\u20138.","DOI":"10.4049\/jimmunol.177.5.3461"},{"key":"10.3238\/arztebl.2011.0399_ref94","doi-asserted-by":"crossref","unstructured":"Shimanovich I, Herzog S, Schmidt E, et al.: Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006; 31: 768\u201374.","DOI":"10.1111\/j.1365-2230.2006.02220.x"},{"key":"10.3238\/arztebl.2011.0399_ref95","doi-asserted-by":"crossref","unstructured":"L\u00fcftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M: Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149: 598\u2013605.","DOI":"10.1046\/j.1365-2133.2003.05513.x"},{"key":"10.3238\/arztebl.2011.0399_ref96","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D: Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241\u201353.","DOI":"10.1007\/s00403-009-1024-9"},{"key":"10.3238\/arztebl.2011.0399_ref97","doi-asserted-by":"crossref","unstructured":"Eming R, Rech J, Barth S, et al.: Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212: 177\u201387.","DOI":"10.1159\/000090659"},{"key":"10.3238\/arztebl.2011.0399_ref98","doi-asserted-by":"crossref","unstructured":"Schmidt E, Goebeler M: CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab. Expert Rev Dermatol 2008; 3: 259\u2013278.","DOI":"10.1586\/17469872.3.3.259"},{"key":"10.3238\/arztebl.2011.0399_ref99","doi-asserted-by":"crossref","unstructured":"Schmidt E, Goebeler M, Zillikens D: Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683\u201391.","DOI":"10.1111\/j.1749-6632.2009.04744.x"},{"key":"10.3238\/arztebl.2011.0399_ref100","doi-asserted-by":"crossref","unstructured":"Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D: Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382\u20138.","DOI":"10.1111\/j.1365-2133.2007.08358.x"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T10:56:39Z","timestamp":1693652199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2011.0399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,10]]},"references-count":100,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2011.0399","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,10]]}}}